Inflammation and bony changes at the temporomandibular joint

Cells Tissues Organs

Volumn 169, Issue 3, 2001, Pages 257-264

  Kacena, Melissa A ^a   Merrel, Greg A ^a   Konda, Sanjit R ^a   Wilson, Kimberly M ^a   Xi, Yougen ^a   Horowitz, Mark C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone degradation; Cytokines; Inflammation; Temporomandibular joint; Temporomandibular joint disorder

Indexed keywords

BONE DEFECT; CLINICAL ARTICLE; CONFERENCE PAPER; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; HUMAN; IMMUNOSTIMULATION; INFLAMMATION; PRIORITY JOURNAL; SYNOVIAL FLUID; TEMPOROMANDIBULAR JOINT; TEMPOROMANDIBULAR JOINT DISORDER;

CASE-CONTROL STUDIES; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; INTERFERON TYPE II; INTERLEUKINS; SYNOVIAL FLUID; TEMPOROMANDIBULAR JOINT; TEMPOROMANDIBULAR JOINT DISORDERS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034948185     PISSN: 14226405     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047889     Document Type: Conference Paper

References (34)

1. Interleukin-1β in synovial fluid from the arthritic temporomandibular joint and its relation to pain, mobility, and anterior open bite
2. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis
3. Chronic inflammatory joint diseases: Natural inhibitors of interleukin 1 and tumor necrosis factor α
4. Normal cartilage structure, biochemistry, and metabolism: A review of the literature
5. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes
6. Determination of interleukin-1 receptor antagonist, interleukin-10, and transforming growth factor-β1 in synovial fluid aspirates of patients with temporomandibular disorders
7. Role of cytokines in rheumatoid arthritis
8. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis
9. Celecoxib, a COX-2-specific inhibitor: The clinical data
10. Tumor necrosis factor in synovial fluid of patients with temporomandibular disorders
11. Etanercept: Therapeutic use in patients with rheumatoid arthritis
12. Synovium as a source of interleukin 6 in vitro
13. Spontaneous temporomandibular joint arthropathy in MRL-Ipr/Ipr mice
14. Concentration of neuropeptides substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid of the human temporomandibular joint
15. Rheumatoid arthritis and disk derangement of the temporomandibular joint
16. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice
17. Synovial tissue macrophage as a source of the chemotactic cytokine IL-8
18. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
19. The influence of neuropeptides, serotonin, and interleukin 1β on temporomandibular joint pain and inflammation
20. Interleukin 1β and stromelysin (MMP3) activity of synovial fluid as possible markers of osteoarthritis in the temporomandibular joint
21. Synovial fluid cytokines and proteinases as markers of temporomandibular joint disease
22. Interleukin-1 receptor antagonist
23. Interleukin-10
24. Production of prostaglandin E2 and collagenase is inhibited by the recombinant soluble tumor necrosis factor receptor p55-human gamma 3 fusion protein at concentrations a hundred-fold lower than those decreasing T cell activation
25. Correlation of inflammatory cytokines with arthroscopic findings in patients with temporomandibular joint internal derangements
26. A human inhibitor of tumor necrosis factor α
27. Purification and biologic characterization of a specific tumor necrosis factor α inhibitor
28. Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production
29. Tumor necrosis factor-α as a biochemical marker of pain and outcome in temporomandibular joints with internal derangements
30. Osteoarthritis as the cause of craniomandibular pain and dysfunction: A unifying concept
31. Proinflammatory cytokines detectable in synovial fluids from patients with temporomandibular disorders
32. Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid
33. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo
34. Interleukin-10 inhibition of the progression of established collagen-induced arthritis